

Gamal Esmat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1731711/publications.pdf>

Version: 2024-02-01

166
papers

4,438
citations

126907

33
h-index

133252

59
g-index

171
all docs

171
docs citations

171
times ranked

5508
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. <i>Liver International</i> , 2011, 31, 61-80.	3.9	481
2	Hepatic and Intestinal Schistosomiasis: Review. <i>Journal of Advanced Research</i> , 2013, 4, 445-452.	9.5	161
3	Screening and Treatment Program to Eliminate Hepatitis C in Egypt. <i>New England Journal of Medicine</i> , 2020, 382, 1166-1174.	27.0	160
4	Human Schistosomiasis: Clinical Perspective: Review. <i>Journal of Advanced Research</i> , 2013, 4, 433-444.	9.5	141
5	Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. <i>Journal of General Virology</i> , 2007, 88, 1526-1531.	2.9	121
6	High Seroprevalence of Hepatitis C Infection among Risk Groups in Egypt. <i>American Journal of Tropical Medicine and Hygiene</i> , 1994, 51, 563-567.	1.4	120
7	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	3.7	114
8	Grading of Hepatic Schistosomiasis by the Use of Ultrasonography. <i>American Journal of Tropical Medicine and Hygiene</i> , 1992, 46, 403-408.	1.4	102
9	Role of hepatitis C infection in chronic liver disease in Egypt.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 67, 436-442.	1.4	102
10	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naïve chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015, 64, 948-956.	12.1	101
11	The current and future disease burden of chronic hepatitis C virus infection in Egypt. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 45-52.	0.9	88
12	Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. <i>Gut</i> , 2010, 59, 1135-1140.	12.1	87
13	A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. <i>Phytomedicine</i> , 2009, 16, 391-400.	5.3	82
14	Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. <i>Journal of Medical Virology</i> , 2021, 93, 5833-5838.	5.0	79
15	Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1624-1630.	2.8	71
16	MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc. <i>Oncology Letters</i> , 2016, 12, 2567-2573.	1.8	66
17	Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 36-44.	8.1	61
18	miR-1275: A single microRNA that targets the three IGF2 mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma. <i>FEBS Letters</i> , 2015, 589, 2257-2265.	2.8	57

#	ARTICLE	IF	CITATIONS
19	Changing Patterns of Acute Viral Hepatitis at a Major Urban Referral Center in Egypt. Clinical Infectious Diseases, 2007, 44, e30-e36.	5.8	51
20	Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic <sc>HCV</sc> genotype <sc>IV</sc> infected patients. Liver International, 2017, 37, 534-541.	3.9	51
21	Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. Journal of Hepatology, 2018, 68, 691-698.	3.7	50
22	Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. Journal of Medical Virology, 2009, 81, 1576-1583.	5.0	47
23	Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. Clinical Rheumatology, 2010, 29, 1373-1380.	2.2	47
24	Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. Human Immunology, 2016, 77, 667-673.	2.4	44
25	Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver International, 2008, 28, 1112-1119.	3.9	43
26	HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Review of Anti-Infective Therapy, 2018, 16, 345-350.	4.4	43
27	Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 843-850.	2.8	42
28	Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. The Lancet Global Health, 2014, 2, e541-e549.	6.3	42
29	HCV-related morbidity in a rural community of Egypt. Journal of Medical Virology, 2006, 78, 1185-1189.	5.0	40
30	New era for management of chronic hepatitis C virus using direct antiviral agents: A review. Journal of Advanced Research, 2015, 6, 301-310.	9.5	40
31	Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. Journal of Medical Virology, 2017, 89, 2181-2187.	5.0	39
32	Impact of Vitamin D Supplementation on Sustained Virological Response in Chronic Hepatitis C Genotype 4 Patients Treated by Pegylated Interferon/Ribavirin. Journal of Interferon and Cytokine Research, 2015, 35, 49-54.	1.2	37
33	WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. Journal of Clinical Gastroenterology, 2021, 55, 1-11.	2.2	37
34	Safety of direct antiviral agents in the management of hepatitis C. Expert Opinion on Drug Safety, 2016, 15, 1643-1652.	2.4	36
35	Abrogating the interplay between IGF2BP1, 2 and 3 and IGF1R by let-7i arrests hepatocellular carcinoma growth. Growth Factors, 2016, 34, 42-50.	1.7	36
36	Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virus-Infected Patients in a Country With Limited Resources: The Case of Egypt. Clinical Infectious Diseases, 2014, 58, 1064-1071.	5.8	34

#	ARTICLE	IF	CITATIONS
37	Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut, 2019, 68, 721-728.	12.1	34
38	Repressed induction of interferon- α -related microRNAs miR-146a and miR-155 in peripheral blood mononuclear cells infected with HCV genotype 4. FEBS Open Bio, 2012, 2, 179-186.	2.3	33
39	Serum α -Foetoprotein Level Predicts Treatment Outcome in Chronic Hepatitis C. Antiviral Therapy, 2007, 12, 797-803.	1.0	33
40	Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comparative Hepatology, 2010, 9, 1.	0.9	31
41	Relation of ALT and AST levels to the histopathological changes in liver biopsies of patients with chronic hepatitis C genotype 4. Arab Journal of Gastroenterology, 2015, 16, 50-53.	0.9	31
42	Impact of Toll-like Receptors 2 (TLR2) and TLR 4 Gene Variations on HCV Susceptibility, Response to Treatment and Development of Hepatocellular Carcinoma in Cirrhotic HCV Patients. Immunological Investigations, 2020, 49, 462-476.	2.0	30
43	Optimizing treatment for <sc>HCV</sc> genotype 4: PEG-IFN α 2a vs. PEG-IFN α 2b; the debate continues. Liver International, 2014, 34, 24-28.	3.9	28
44	Human cytomegalovirus infection inhibits response of chronic hepatitis C virus-infected patients to interferon-based therapy. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 55-62.	2.8	27
45	Strong Hepatitis C Virus (HCV)-specific Cell-mediated Immune Responses in the Absence of Viremia or Antibodies Among Uninfected Siblings of HCV Chronically Infected Children. Journal of Infectious Diseases, 2011, 203, 854-861.	4.0	27
46	Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Review of Gastroenterology and Hepatology, 2017, 11, 773-778.	3.0	27
47	Managing diabetes and liver disease association. Arab Journal of Gastroenterology, 2018, 19, 166-179.	0.9	27
48	Epigallocatechin gallate (EGCG) and miR-548m reduce HCV entry through repression of CD81 receptor in HCV cell models. Archives of Virology, 2019, 164, 1587-1595.	2.1	27
49	Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. Pediatric Diabetes, 2010, 11, 462-470.	2.9	26
50	Accurate Prediction of Advanced Liver Fibrosis Using the Decision Tree Learning Algorithm in Chronic Hepatitis C Egyptian Patients. Gastroenterology Research and Practice, 2016, 2016, 1-7.	1.5	26
51	One step closer to elimination of hepatitis C in Egypt. The Lancet Gastroenterology and Hepatology, 2018, 3, 665.	8.1	26
52	How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. Hepatology, 2015, 62, 31-39.	7.3	25
53	FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab Journal of Gastroenterology, 2016, 17, 78-83.	0.9	25
54	Losartan may inhibit the progression of liver fibrosis in chronic HCV patients. Hepatobiliary Surgery and Nutrition, 2016, 5, 249-255.	1.5	24

#	ARTICLE	IF	CITATIONS
55	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	3.9	24
56	Is <i>Schistosoma mansoni</i> Replacing <i>Schistosoma haematobium</i> in the Fayoum?. <i>American Journal of Tropical Medicine and Hygiene</i> , 1993, 49, 697-700.	1.4	24
57	Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. <i>Liver International</i> , 2012, 32, 449-456.	3.9	22
58	A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2015, 12, 645-650.	2.4	22
59	Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. <i>Liver International</i> , 2020, 40, 797-805.	3.9	22
60	Diabetes Association with Liver Diseases: An Overview for Clinicians. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019, 19, 274-280.	1.2	22
61	Fibroscan of chronic HCV patients coinfectd with schistosomiasis. <i>Arab Journal of Gastroenterology</i> , 2013, 14, 109-112.	0.9	20
62	Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. <i>Oncology Letters</i> , 2015, 10, 3206-3212.	1.8	20
63	Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor. <i>Journal of Infection</i> , 2015, 70, 78-87.	3.3	20
64	An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1265-1272.	3.0	20
65	Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2019, 91, 272-277.	5.0	20
66	Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. <i>Archives of Virology</i> , 2013, 158, 1755-1764.	2.1	19
67	Expression signature of microRNA-155 in hepatitis C virus genotype 4 infection. <i>Biomedical Reports</i> , 2015, 3, 93-97.	2.0	19
68	Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1008-1016.	1.6	19
69	Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions. <i>World Journal of Gastroenterology</i> , 2018, 24, 1228-1238.	3.3	19
70	Novel scores combining AFP with noninvasive markers for prediction of liver fibrosis in chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2018, 90, 1080-1086.	5.0	18
71	NS5A Sequence Heterogeneity of Hepatitis C Virus Genotype 4a Predicts Clinical Outcome of Pegylated-Interferon-Ribavirin Therapy in Egyptian Patients. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3886-3892.	3.9	17
72	Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. <i>Journal of Hepatology</i> , 2018, 68, 53-62.	3.7	17

#	ARTICLE	IF	CITATIONS
73	Egyptian recommendations for management of Helicobacter pylori infection: 2018 report. Arab Journal of Gastroenterology, 2019, 20, 175-179.	0.9	17
74	Hepatitis C Virus in Egypt: Interim Report From the World's Largest National Program. Clinical Liver Disease, 2019, 14, 203-206.	2.1	16
75	Predictors of severity and development of critical illness of Egyptian COVID-19 patients: A multicenter study. PLoS ONE, 2021, 16, e0256203.	2.5	16
76	Excess mortality rate associated with hepatitis C virus infection: A community-based cohort study in rural Egypt. Journal of Hepatology, 2016, 64, 1240-1246.	3.7	15
77	Contradicting roles of miR-182 in both NK cells and their host target hepatocytes in HCV. Immunology Letters, 2016, 169, 52-60.	2.5	15
78	Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver International, 2018, 38, 2159-2169.	3.9	15
79	Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort. Liver International, 2021, 41, 1494-1497.	3.9	15
80	How to optimize HCV therapy in genotype 4 patients. Liver International, 2013, 33, 41-45.	3.9	14
81	Ophthalmological side effects of interferon therapy of chronic hepatitis C. Hepatobiliary Surgery and Nutrition, 2016, 5, 209-216.	1.5	14
82	Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Review of Clinical Pharmacology, 2016, 9, 1413-1421.	3.1	13
83	Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. Expert Opinion on Drug Discovery, 2017, 12, 635-642.	5.0	13
84	Comparing the efficiency of Fib-4, Forns score, APRI, and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C. Journal of Medical Virology, 2018, 90, 1106-1111.	5.0	13
85	Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review. Journal of Advanced Research, 2019, 17, 43-48.	9.5	13
86	Clinical impact of serum Î-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. European Journal of Gastroenterology and Hepatology, 2019, 31, 1129-1134.	1.6	13
87	HCV and HEV: two players in an Egyptian village, a study of prevalence, incidence, and co-infection. Environmental Science and Pollution Research, 2020, 27, 33659-33667.	5.3	13
88	Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Review of Anti-Infective Therapy, 2020, 18, 637-642.	4.4	13
89	Epidermal growth factor gene polymorphism 61A/G in patients with chronic liver disease for early detection of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	1.6	13
90	Estrogen-related MxA transcriptional variation in hepatitis C virus-infected patients. Translational Research, 2012, 159, 190-196.	5.0	12

#	ARTICLE	IF	CITATIONS
91	Predictive prognostic role of miR-181a with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients. Biomedical Reports, 2014, 2, 843-848.	2.0	12
92	Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. Frontiers in Physiology, 2018, 9, 1918.	2.8	12
93	Circulating microRNAs (miR-21, miR-223, miR-885-5p) along the clinical spectrum of HCV-related chronic liver disease in Egyptian patients. Arab Journal of Gastroenterology, 2019, 20, 198-204.	0.9	12
94	The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi Journal of Gastroenterology, 2022, 28, 3.	1.1	12
95	Herpes Zoster reactivation in patients with chronic hepatitis C under treatment with directly acting antiviral agents: A case series. Arab Journal of Gastroenterology, 2017, 18, 39-41.	0.9	10
96	Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study. International Immunopharmacology, 2021, 99, 108004.	3.8	10
97	Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2013, 25, 628-633.	1.6	9
98	Ectopic delivery of miR-200c diminishes hepatitis C virus infectivity through transcriptional and translational repression of Occludin. Archives of Virology, 2017, 162, 3283-3291.	2.1	9
99	Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models. Frontiers in Genetics, 2018, 9, 93.	2.3	9
100	Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles. Journal of Infection and Public Health, 2020, 13, 1322-1329.	4.1	9
101	Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1. European Journal of Gastroenterology and Hepatology, 2010, 22, 450-456.	1.6	8
102	Accurate Prediction of Response to Interferon-based Therapy in Egyptian Patients with Chronic Hepatitis C Using Machine-learning Approaches. , 2012, , .		8
103	Repressing PU.1 by miR-29a in NK cells of HCV patients, diminishes its cytolytic effect on HCV infected cell models. Human Immunology, 2015, 76, 687-694.	2.4	8
104	Extrahepatic manifestations in hepatitis C virus infection. Journal of Advanced Research, 2017, 8, 85-87.	9.5	8
105	DAA's therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV. Expert Review of Gastroenterology and Hepatology, 2019, 13, 693-698.	3.0	8
106	Predictors of Virological Response in 3,235 Chronic HCV Egyptian Patients Treated with Peginterferon Alpha-2a Compared with Peginterferon Alpha-2b Using Statistical Methods and Data Mining Techniques. Journal of Interferon and Cytokine Research, 2016, 36, 338-346.	1.2	7
107	miR-148a and miR-30a limit HCV-dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models. Journal of Medical Virology, 2017, 89, 653-659.	5.0	7
108	High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience. European Journal of Gastroenterology and Hepatology, 2018, 30, 1194-1199.	1.6	7

#	ARTICLE	IF	CITATIONS
109	Seroprevalence of HCV among Cairo University students in Egypt. <i>Journal of Medical Virology</i> , 2016, 88, 1384-1387.	5.0	6
110	Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients. <i>Acta Tropica</i> , 2017, 176, 283-287.	2.0	6
111	A New Potent NS5A Inhibitor in the Management of Hepatitis C Virus: Ravidasvir. <i>Current Drug Discovery Technologies</i> , 2018, 15, 24-31.	1.2	6
112	Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 882-887.	1.6	6
113	Anticancer activity of milk fat rich in conjugated linoleic acid against Ehrlich ascites carcinoma cells in female Swiss albino mice. <i>Veterinary World</i> , 2021, 14, 696-708.	1.7	6
114	Antischistosomal therapy: Current status and recent developments. <i>Arab Journal of Gastroenterology</i> , 2009, 10, 1-3.	0.9	5
115	Quality of life of Egyptian donors after living-related liver transplantation. <i>Arab Journal of Gastroenterology</i> , 2009, 10, 21-24.	0.9	5
116	Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	3.0	5
117	Epigenetic harnessing of HCV via modulating the lipid droplet-associated protein, TIP47, in HCV cell models. <i>FEBS Letters</i> , 2015, 589, 2266-2273.	2.8	5
118	Diagnostic accuracy of the γ -glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4. <i>Gut</i> , 2016, 65, 1577-1578.	12.1	5
119	Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 81-85.	1.2	5
120	Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1009-1016.	3.0	5
121	Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2020, 114, 232-240.	1.8	5
122	Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome. <i>Platelets</i> , 2021, 32, 383-390.	2.3	5
123	Management of liver disease patients in different clinical situations during COVID-19 pandemic. <i>Egyptian Liver Journal</i> , 2021, 11, 21.	0.6	5
124	miR-34a: Multiple Opposing Targets and One Destiny in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 300-305.	1.4	5
125	Study of the enhancing effect of sodium chloride injection on radiofrequency ablation of hepatocellular carcinoma. <i>Arab Journal of Gastroenterology</i> , 2009, 10, 63-67.	0.9	4
126	Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 348-353.	1.2	4

#	ARTICLE	IF	CITATIONS
127	After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal. Journal of Clinical Laboratory Analysis, 2018, 32, .	2.1	4
128	Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience. Journal of Medical Virology, 2019, 91, 668-676.	5.0	4
129	High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study. Expert Review of Gastroenterology and Hepatology, 2019, 13, 907-914.	3.0	4
130	Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Expert Review of Anti-Infective Therapy, 2021, , 1-8.	4.4	4
131	Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. Annals of Gastroenterology, 2014, 27, 380-386.	0.6	4
132	Establishing ultrasound based transient elastography cutoffs for different stages of hepatic fibrosis and cirrhosis in Egyptian chronic hepatitis C patients. Arab Journal of Gastroenterology, 2017, 18, 210-215.	0.9	3
133	The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents. Expert Review of Gastroenterology and Hepatology, 2021, 15, 103-110.	3.0	3
134	HCV/HIV coinfectd Egyptian patients: a cross-sectional study of their main characteristics and barriers to HCV treatment initiation. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 227-232.	1.8	3
135	Antiretroviral therapy optimisation in the time of COVID-19: Is it really different in North and South Africa?. Southern African Journal of HIV Medicine, 2020, 21, 1118.	0.9	3
136	Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. Journal of Viral Hepatitis, 2022, 29, 474-486.	2.0	3
137	Tamoxifen downregulates MxA expression by suppressing TLR7 expression in PBMCs of males infected with HCV. Journal of Medical Virology, 2014, 86, 1113-1119.	5.0	2
138	Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. BMC Medical Research Methodology, 2014, 14, 39.	3.1	2
139	Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. Advances in Therapy, 2016, 33, 1797-1813.	2.9	2
140	Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay. High-Throughput, 2017, 6, 15.	4.4	2
141	Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. Infection, 2020, 48, 913-922.	4.7	2
142	Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. Arab Journal of Gastroenterology, 2021, 22, 75-87.	0.9	2
143	Micro-elimination of hepatitis C among people living with HIV in Egypt. Liver International, 2021, 41, 1445-1447.	3.9	2
144	Hepatitis C elimination in Africa: Seizing the moment for hepatitis-C free future. Arab Journal of Gastroenterology, 2021, 22, 249-251.	0.9	2

#	ARTICLE	IF	CITATIONS
145	COVID-19 crisis effect on HIV service delivery in Egypt: Hard times or blessings in disguise?. Southern African Journal of HIV Medicine, 2020, 21, 1170.	0.9	2
146	Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. Expert Review of Anti-Infective Therapy, 2022, 20, 789-795.	4.4	2
147	Eliminating hepatitis C from countries with high prevalence: When infrastructure comes first. Indian Journal of Medical Research, 2021, 154, 1.	1.0	2
148	HIV-related stigma and discrimination by healthcare workers in Egypt. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, , .	1.8	2
149	Epstein-Barr virus and Interleukin-28B polymorphism in the prediction of response to interferon therapy in hepatitis C patients. Arab Journal of Gastroenterology, 2015, 16, 84-89.	0.9	1
150	Response to Real life Egyptian experience of Efficacy / safety of Simeprevir Sofosbuvir in HCV genotype IV. Liver International, 2017, 37, 766-766.	3.9	1
151	Real-Life Efficacy of 5 Different Antiviral Regimens for Treatment of Chronic Hepatitis C With Normal Liver Enzymes. American Journal of Therapeutics, 2018, 25, e776-e779.	0.9	1
152	Derivation of the Egyptian varices prediction (EVP) index: A novel noninvasive index for diagnosing esophageal varices in HCV Patients. Journal of Advanced Research, 2022, 35, 87-97.	9.5	1
153	Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	1.6	1
154	OUP accepted manuscript. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, , .	1.8	1
155	Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment. Gastroenterology Research, 2014, 7, 56-63.	1.3	1
156	Egyptian revalidation of non-invasive parameters for predicting esophageal varices in cirrhotic patients: A retrospective study. Arab Journal of Gastroenterology, 2022, 23, 120-124.	0.9	1
157	Management of Hepatitis C Virus Genotypes 4, 5, and 6 Using Direct Antiviral Agents: Review of Current Status. Current Treatment Options in Infectious Diseases, 2016, 8, 368-378.	1.9	0
158	OUP accepted manuscript. Journal of Public Health, 2021, , .	1.8	0
159	Hepatitis C viral RNA in blood mononuclear cells of patients treated with directly acting antivirals. Arab Journal of Gastroenterology, 2021, 22, 158-163.	0.9	0
160	HLA Tissue Typing Has No Effect on the Outcome of Patients Undergoing a Living-donor Liver Transplant: A Single-center Experience in Egypt. Experimental and Clinical Transplantation, 2012, 10, 136-140.	0.5	0
161	Parasitic Liver Disease. , 2018, , 568-578.e4.		0
162	OUP accepted manuscript. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, , .	1.8	0

#	ARTICLE	IF	CITATIONS
163	HCV Infection Amplified Th2 Bias and Th17 Responses In Schistosoma-Infected Patients. The Egyptian Journal of Immunology / Egyptian Association of Immunologists, 2016, 23, 87-96.	0.4	0
164	IL-17 Induced The Recruitment and Functional Activity of Granulocytes Isolated from Patients Coinfected with Schistosoma mansoni and Hepatitis C Virus. The Egyptian Journal of Immunology / Egyptian Association of Immunologists, 2017, 24, 9-20.	0.4	0
165	Dose-Dependent Ivermectin Effect on COVID-19 Polymerase Chain Reaction Status. American Journal of Therapeutics, 2024, 31, e72-e81.	0.9	0
166	The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection. Asian Pacific Journal of Cancer Prevention, 2022, 23, 1365-1372.	1.2	0